Psst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveCLEATUS Webinar: AI for Government Contracting — Free Webinar — Wednesday, August 19 at 2:00 PM EDT

Register Free →

Search

Top

COX, SUZANNE

UEI: M2S1N7ET1FC3

COX, SUZANNE is a federal contractor, registered under UEI M2S1N7ET1FC3. It has been awarded $222,598 across 3 federal contracts. Primary work spans Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology) and Research and Development in Biotechnology. Top awarding agencies include Environmental Protection Agency.

Contact Information

Registration and classification details

Registration

UEI Code

M2S1N7ET1FC3

Federal Contracting Overview

Award totals, agency breakdown, NAICS distribution, and geographic footprint.

Key Performance Metrics

Awards Count

0

All time

Active

0

Currently performing

Completed

0

Past period of performance

Total Awards

All time

Contracts

Prime · all time

Subcontracts

Sub · all time

Grants

Prime · all time

Subgrants

Sub · all time

Award Analytics & Distribution

Awards by Agency

Environmental Protection Agency$222.6K100%

Awards by NAICS

541712 - Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)$163.5K73.5%

541711 - Research and Development in Biotechnology$59.1K26.5%

Awards by Agency Over Time

Awards by Place of Performance

Open opportunities in COX, SUZANNE's top NAICS codes and agencies

CAM ASSEMBLY, LOWER,

Solicitation # SPE7M4-26-T-299C

The contract pertains to the procurement of a CAM ASSEMBLY, LOWER, identified by part number 74A430615-1001 and NSN 1710-01-478-1569, with a total quantity of 21 units at a unit price of $21.00, resulting in a total contract value of $441.00. Delivery is required within 590 days from the contract award, with FOB origin terms and final inspection and acceptance occurring at the destination. The item is classified as a critical application component, subject to stringent quality verification standards, including zero non-conformances in sampling under MIL-STD-1916 or comparable zero-based plans, with critical, major, and minor attributes assigned specific verification levels or AQLs. Packaging must align with ASTM D3951 and MIL-STD-129 labeling requirements, prioritizing DLA Master List of Technical and Quality Requirements over any conflicting standards, and palletization must comply with RP001 DLA packaging guidelines. The contractor must maintain CMMC Level 2 cybersecurity self-assessment compliance and adhere to all applicable technical and quality references listed in the DLA Master List. The delivery destination is DLA Distribution San Diego at 3581 Cummings Road, Building 3581, San Diego, CA 92136-3581, with a required ship date of June 18, 2026, and an original delivery deadline of February 10, 2029. The solicitation number is SPE7M4-26-T-299C, with a response deadline of August 14, 2026, issued under NAICS code 541712 by the Department of Defense’s Fluid Handling Division, and is managed by point of contact Rory O’Reilly.

FLUID HANDLING DIVISION

POSTED

DEADLINE

In Vitro ADMET AssaysThe contract titled In Vitro ADMET Assays calls for the performance of high-throughput in vitro screening focused on metabolic stability, hepatotoxicity, CYP450 enzyme interactions, and cellular permeability to support early-stage drug development. These assays are critical for evaluating the absorption, distribution, metabolism, excretion, and toxicity profiles of potential therapeutic candidates, enabling informed decisions before advancing compounds into costly clinical stages. The work will be conducted to meet the specific needs of the National Institutes of Health NIDA under the Department of Health and Human Services, with performance expected to occur in Bethesda. This is a subcontract opportunity under NAICS code 541711, which classifies it as research and development in the physical, engineering, and life sciences. The solicitation was posted on August 3, 2026, with a response deadline of August 18, 2026, at 7:00 PM Eastern Time. There is no set-aside classification specified, and no point of contact or detailed office address is provided in the data. Interested parties must submit their proposals before the deadline to be considered for award, with the expectation that the selected contractor will deliver reliable, scalable, and scientifically rigorous ADMET data to guide NIDA’s research initiatives in drug development.

National Institutes Of Health Nida

POSTED

DEADLINE

Genotoxicity and Carcinogenicity TestingThe contract seeks to perform in vitro and in vivo assays to assess the mutagenic and carcinogenic risks of drug candidates, ensuring compliance with regulatory safety standards for pharmaceutical development. The work is critical for identifying potential genetic toxicity and cancer-causing properties early in the drug evaluation process to support regulatory submissions and public health safeguards. The solicitation is issued as a subcontract under the National Institutes of Health NIDA, part of the Department of Health and Human Services, with performance expected to take place in Bethesda. It falls under the NAICS code 541711 for research and development in the physical, engineering, and life sciences. The proposal must be submitted by August 18, 2026, with the opportunity posted on August 3, 2026. No set-aside provisions are specified, and the contract is open to qualified subcontractors with the technical capacity to deliver high-quality genotoxicity and carcinogenicity testing services.

National Institutes Of Health Nida

POSTED

DEADLINE

Safety Pharmacology (CNS, Cardiovascular, Pulmonary)The contract requires comprehensive safety pharmacology studies to evaluate adverse effects on the central nervous system, cardiovascular system, and pulmonary function, ensuring alignment with ICH safety guidelines. The work will involve detailed pharmacodynamic assessments to identify and characterize potential risks to major organ systems during early drug development, with a focus on identifying safety signals that could impact clinical translation. This subcontract, issued by the National Institutes of Health’s NIDA under the Department of Health and Human Services, is set to be performed in Bethesda and has a response deadline of August 18, 2026. The effort is classified under NAICS code 541711, indicating it pertains to research and development in the life sciences, and is aimed at supporting regulatory-compliant preclinical safety evaluations essential for pharmaceutical advancement.

National Institutes Of Health Nida

POSTED

DEADLINE

Toxicity Testing (Acute, Subacute, Subchronic, Chronic)The contract requires the performance of comprehensive toxicity testing in both rodent and non-rodent models to assess organ toxicity and establish safety margins for submission to regulatory authorities as part of an Investigational New Drug application. The scope includes acute, subacute, subchronic, and chronic studies designed to evaluate the potential adverse effects of pharmaceutical compounds across a range of exposure durations and dosages. The work must meet rigorous scientific standards to support regulatory filings and ensure the safety profile of investigational drugs is adequately characterized prior to human trials. This subcontract is issued under the National Institutes of Health, National Institute on Drug Abuse, within the Department of Health and Human Services, with the performance location specified as Bethesda. The North American Industry Classification System code 541711 identifies the work as research and development in the life sciences. The solicitation was posted on August 3, 2026, with a mandatory response deadline of August 18, 2026, at 7:00 PM. No set-aside provisions are specified, and the contract opportunity is open to eligible contractors capable of executing preclinical toxicology studies to support IND submissions.

National Institutes Of Health Nida

POSTED

DEADLINE

In Vivo Pharmacokinetic StudiesThe contract seeks to perform in vivo pharmacokinetic studies to assess the absorption, distribution, metabolism, and excretion of a drug candidate in both rodent and non-rodent species across multiple administration routes, with the goal of generating data to support an Investigational New Drug application. These studies will evaluate drug exposure over time to establish pharmacokinetic profiles critical for regulatory submission, requiring rigorous experimental design, appropriate species selection, and adherence to good laboratory practices. All work must be completed to ensure high-quality, reproducible results that meet FDA expectations for preclinical development. The solicitation is classified as a subcontract under NAICS code 541711, issued by the National Institutes of Health through the National Institute on Drug Abuse, part of the Department of Health and Human Services. Performance is expected to take place in Bethesda, and interested parties must submit their responses no later than August 18, 2026, at 7:00 PM. The opportunity was posted on August 3, 2026, and is open for competitive bidding with no specific set-aside designation. The contract does not provide a point of contact, and all inquiries must be directed through the official SAM.gov portal linked in the posting.

National Institutes Of Health Nida

POSTED

DEADLINE

BUSHING-TORQUE ARM,

Solicitation # SPE7L3-26-T-144T

The contract is for the procurement of 38 units of a Bushing-Torque Arm, identified by NSN 1710-01-478-1872 and critical part number 74A430625-2001, sourced from approved manufacturers The Boeing Company and Safran Landing Systems Canada Inc. This is a critical application item procured under solicitation SPE7L3-26-T-144T, issued by the Defense Logistics Agency Land and Maritime, with delivery required to DLA Distribution San Diego at 3581 Cummings Road, Building 3581, San Diego, CA 92136-3581. The unit price is $38.00 per unit, with FOB Origin terms, zero quantity variance allowed, and delivery required within 347 days of contract award, with an original delivery date of April 15, 2026, and an early need ship date of February 4, 2025. All supplies must comply with the DLA Master List of Technical and Quality Requirements, which override any conflicting standards such as ASTM D3951, and must be packaged, marked, and labeled per MIL-STD-129 and RP001, with palletization following DLA packaging standards. Sampling for inspection must adhere to MIL-STD-1916, ASQ H1331 Table 1, or an equivalent zero-based plan, with unspecified attributes treated as major and zero non-conformances required unless otherwise stated. Inspection and acceptance occur at destination under FAR 52.246-2. The item is exempt from additive manufacturing unless explicitly authorized. The contractor must electronically submit invoices and receiving reports via WAWF, comply with all cybersecurity mandates including DFARS 252.204-7012 and NIST SP 800-171, and adhere to the prohibition of hexavalent chromium, covered telecommunications equipment, and communist Chinese military company items. The Berry Amendment applies, requiring domestic origin materials above $150,000, and safety data sheets must be provided prior to award. Contractors must be registered in SAM and AMPS for DLA shipments, and all bids must be submitted via DIBBS by August 13, 2026. The contract includes mandatory clauses covering whistleblower protections, cyber incident reporting

LAND SUPPLIER OPNS VEHICLE SPT

POSTED

DEADLINE

Influenza Vaccine Clinical Trial ManagementThe contract pertains to the design and management of Phase I–III clinical trials for influenza vaccines, encompassing all critical aspects from protocol development and site selection to patient recruitment and regulatory reporting to the FDA. The work requires specialized expertise in infectious disease trials, with a focus on ensuring compliance with regulatory standards and timely submission of clinical data. The performance location is in Washington, DC, with a zip code of 20024, indicating the primary operational base for trial oversight and coordination. This is a subcontract under the Department of Health and Human Services, specifically managed by Barda – ASPR / DAAPPO / Barda DCMA, with a NAICS code of 541711 indicating scientific research and development services. The opportunity was posted on July 30, 2026, with a response deadline of August 15, 2026, at 9:00 PM ET. While no set-aside type or point of contact is specified, the emphasis on end-to-end clinical trial management suggests the subcontractor must possess a proven track record in vaccine development, regulatory engagement, and multi-site trial execution under federal health security initiatives.

Barda - Aspr / Daappo / Barda Dcma

POSTED

DEADLINE

Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.

Aspr Administration For Strategic Preparedness And Response

POSTED

DEADLINE

Induced Pluripotent Stem Cell (iPSC) Reprogramming ServicesThe contract entails the reprogramming of human articular chondrocytes and bone marrow cells into induced pluripotent stem cells using Sendai virus technology, with full support for culture expansion and cryopreservation of the resulting iPSCs. This subcontract is part of a research initiative led by the Department of Veterans Affairs through Rpo East, focused on advancing regenerative medicine techniques through advanced cellular reprogramming methods. The work requires precise adherence to protocols ensuring high efficiency, safety, and scalability of iPSC generation while maintaining cell viability and pluripotency throughout the process. The solicitation is open for responses until August 6, 2026, and falls under NAICS code 541711, indicating it is for research and development in the biological sciences. The agreement is structured as a subcontract, suggesting it will be awarded to a specialized contractor with expertise in stem cell biology and virology-based reprogramming. Performance is expected to meet rigorous quality standards for cellular products intended for potential therapeutic or diagnostic applications, with an emphasis on reproducibility and documentation. All deliverables must include verified iPSC lines archived through cryopreservation, ready for downstream use in future studies or clinical translation.

Rpo East (36C24E)

POSTED

DEADLINE

in about 15 hours

Trailblazers CDRL Services

FA8811 Assrd Acss To Spc Ssc/aak-La

POSTED

DEADLINE

in about 23 hours

Explosives Detection & Threat Mitigation Technology Development

Sci Technology Acq Division

POSTED

DEADLINE

Emerging Animal & Zoonotic Disease Diagnostics Research

Sci Technology Acq Division

POSTED

DEADLINE

Pax Silica Artificial Intelligence Assistance Project

Solicitation # DFOP0019182

The Pax Silica Artificial Intelligence Assistance Project, funded through foreign assistance from the Pax Fund and issued under solicitation number DFOP0019182 by the Department of State’s Bureau of Oceans - Interior Environmental - Scientific, aims to establish a first-of-its-kind global platform to secure the AI supply chain through cryptographic cargo verification, AI-driven risk assessment, and expedited compliance processes. This initiative will create a Silicon Highway—a digital-physical corridor connecting partner countries—to enhance logistics efficiency and supply chain integrity by enabling trusted provenance tracking and pre-approved accelerated processing from the earliest stages of the AI hardware and software supply chain. The program is designed to build resilience against tampering, counterfeiting, and disruptions in critical AI components by institutionalizing a globally recognized credentialing system. The project is open to applicants responding by the deadline of August 20, 2026, with all proposals submitted through the grants.gov portal. The Bureau of Oceans - Interior Environmental - Scientific is the responsible agency, and while the place of performance is not specified, the point of contact is available through the provided phone number. The Department of State retains full rights to any intangible property developed under this initiative, in accordance with federal regulations. Participation is expected to involve international collaboration, technical innovation, and the integration of advanced digital tools to ensure transparency and security across the global AI supply chain.

Bureau Of Oceans - Interior Environmental - Scientific

POSTED

about 1 month ago

DEADLINE

Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Biomedical Research ExecutionThis contract enables a collaborative biomedical research effort focused on neurofibromatosis, requiring coordinated hypothesis-driven investigations led by an Initiating Principal Investigator and a Partnering Principal Investigator. The work encompasses the design of experiments, generation of empirical data, and rigorous milestone-based progress reporting to ensure scientific rigor and accountability. The project is structured as a subcontract under the Defense Health Agency Contracting Activity, falling under the NAICS code for research and development in the physical, engineering, and life sciences, and is intended to advance understanding of neurofibromatosis through integrated scientific contributions. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is managed by the Department of Defense through its health research infrastructure. While no set-aside provisions or specific location details are provided, the emphasis is firmly on outcome-driven research with clearly defined deliverables tied to research milestones. The effort requires close alignment between the two principal investigators to ensure cohesive experimental planning, data integrity, and timely reporting, reflecting a strategic investment in translational medical science with potential implications for defense-relevant health conditions.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 1 month ago

DEADLINE

in about 2 months

Collaborative Research Partnership (Partnering PI Option)This contract establishes a collaborative research partnership where a Partnering Principal Investigator from an external institution will co-lead the research effort alongside the primary team, sharing equal responsibility for scientific direction, project management, and deliverables. Funding is jointly allocated between the participating institutions, ensuring aligned resources and mutual accountability for outcomes, with the work focused on health-related research under the Defense Health Agency Contracting Activity. The initiative falls under NAICS code 541711, indicating it is within the scientific research and development sector, and is structured as a subcontract to support integrated, multi-institutional innovation. The opportunity was posted on June 18, 2026, with a deadline for responses set for September 28, 2026, providing potential partners a defined window to submit proposals. The partnership is expected to be conducted in alignment with the mission of the Department of Defense, addressing critical health priorities through joint scientific leadership. There is no set-aside designation specified, meaning eligibility is open to qualified institutions regardless of size or status, and no specific location is designated for performance, allowing flexibility in where the research activities are carried out as long as the objectives are met collaboratively.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 2 months

Kidney Cancer Clinical Research ExecutionThe contract titled Kidney Cancer Clinical Research Execution aims to advance clinical and translational research focused on kidney cancer through comprehensive scientific activities including study design, patient data collection, biomarker analysis, and therapeutic development. The work is intended to support the development of innovative treatments and diagnostic strategies by integrating clinical observations with laboratory research, ensuring findings are rapidly translated into improved patient outcomes. The project requires expertise in oncology research methodologies, rigorous data management, and interdisciplinary collaboration to address critical gaps in kidney cancer understanding and care. This subcontract is issued by the Defense Health Agency Contracting Activity under the Department of Defense and falls under NAICS code 541711, indicating it is related to research and development in the life sciences. The opportunity was posted on June 18, 2026, with a response deadline of September 28, 2026, providing potential applicants approximately three months to prepare and submit proposals. The place of performance and specific office address details are not specified, suggesting flexibility in location but requiring proposers to align with the overarching objectives of the Department of Defense’s medical research priorities. All work must demonstrate scientific excellence, feasibility, and direct relevance to advancing kidney cancer therapeutics within a clinical context.

Defense Health Agency Contracting Activity - Dhaca

POSTED

about 2 months ago

DEADLINE

in about 2 months